Research and Markets: Lung Cancer Drug Futures 2010 - All New Web Service Assessing the Future Prospects for Market Succes

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/e8f110/lung_cancer_drug_f) has announced the addition of the "Lung Cancer Drug Futures 2010" report to their offering.

Although a plethora of platinum-based chemotherapy combinations may be prescribed for the treatment of non small cell lung cancer (NSCLC) the market is currently driven by chemotherapeutic agents such as taxanes and antimetabolites, and the increasing use of targeted therapies. Some of the newer chemotherapy agents such as Eli Lilly's Gemzar and Alimta have become the standard of care in combination with cisplatin or carboplatin and may be used in addition to or instead of the taxanes Taxotere or Taxol/generic paclitaxel.

The lung cancer market is set for radical change. A number of current first-line therapies will become subject to generic competition in the short term. Although chemotherapy will continue to play a significant if diminishing role, industry attention is firmly on the better-tolerated biologics which are already setting the pace in the market and whose influence will grow over the coming years. In 2007, chemotherapy treatments accounted for 68% of the market but are forecast to account for only 32% by 2014, whereas targeted treatments are forecast to increase from 30% to 60% over the same period.

As researchers begin to understand the processes involved in NSCLC formation, several new targeted therapies have evolved which modulate growth factor pathways. For example, Roches small-molecule tyrosine kinase inhibitor Tarceva (erlotinib) and its best selling anti-angiogenic VEGF inhibitor Avastin (bevacizumab) are gaining credence in second- and first-line therapy for advanced disease, respectively.

NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER:

This all new web service, Lung Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.

WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN:

  • Track the drugs progress and stay abreast of developments
  • Understand the drugs novelty and mode of action
  • Evaluate the strength of the company developing/producing the drug
  • Review opportunities and challenges with the analysts unique 5-point competitive assessment
  • Know the launch timeframe for new products or indications
  • Be aware of promising mid-stage development candidates
  • Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates
  • Review significant clinical trial results

STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCES:

For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include:

  • Novelty/rationale for mechanism of action
  • Current status
  • Proof of concept/clinical data
  • Development risks
  • Company expertise
  • Competition within the market-place
  • Sales forecast (for key late-stage and launched products)
  • Competitor ratio analysis score
  • Clinical trial results

OVER 45 CURRENT DRUGS COVERED:

Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.

To view all current drugs covered in this report and for more information visit http://www.researchandmarkets.com/research/e8f110/lung_cancer_drug_f

Source: Espicom Business Intelligence Ltd



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   Europe  Ireland

INDUSTRY KEYWORDS:   Health  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.